Compare Inovio Pharmaceuticals Inc (INO) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Exxon Mobil Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Exxon Mobil Corporation trades at $151.71 (market cap $614.94B). The key difference: Exxon Mobil Corporation is far larger — about 6888.5× Inovio Pharmaceuticals Inc's market cap, and Exxon Mobil Corporation pays a 2.78% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | XOM | |
|---|---|---|
Market Cap | $89.27M | $614.94B |
Sector | Health | Energy |
52-Week High | $2.87 | $171.52 |
52-Week Low | $1.05 | $105.83 |
Enterprise Value | $60.28M | $654.17B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
ExxonMobil (XOM) trades at $147.39, up 0.99% today, with a bullish technical signal from moving averages and oscillators. The stock has beaten earnings estimates for the last three quarters, though revenue and net income have trended lower since 2022. Analyst consensus is a buy with a $169.78 price target, and recent news highlights the company's Permian Basin advantage and potential oil price spikes.
XOM offers value through strong cash flow and a robust balance sheet, but faces headwinds from declining profitability and net cash outflows. Investment appeal hinges on oil price stability and execution in key growth areas, while risks include volatile energy markets and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
